| 查看: 623 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
[求助]
翻译一段摘要，非常感谢
|
||
|
Abstract Purpose To assess the e cacy and toxicity of an oralY anticancer uoropyrimidine derivative, S-1, for previouslyX treated patients with advanced non-small cell lung cancer (NSCLC). Patients and methods Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6weeks. Results Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% con dence intervalW (95%CI), 3.1–21.9%). Disease control rate was 39.6% (19/ 48) (95%CI, 25.7–53.4%). Median progression-free sur- vival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxici- ties comprised neutropenia in one patient (2.1%) and ane- mia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only ve patients (10.4%).W Treatment-related death did not occur. Conclusion S-1 is an active and well-tolerated mono- therapy for second-line treatment of advanced NSCLC. [ Last edited by 霜叶 on 2013-2-27 at 10:32 ] |
回复此楼» 猜你喜欢
281求调剂
已经有6人回复
-
华南理工0703化学，总分336求调剂
已经有6人回复
-
285求调剂
已经有12人回复
-
085600材料与化工301分求调剂院校
已经有13人回复
-
295求调剂
已经有11人回复
-
材料与化工专硕306分找合适调剂
已经有3人回复
-
0703调剂，一志愿天津大学319分
已经有11人回复
-
求调剂
已经有21人回复
-
材料专硕(0856) 339分求调剂
已经有10人回复
-
319求调剂
已经有3人回复
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
phu_grassman: 金币+20, 翻译EPI+1, thanks for your time and energy 2013-03-01 13:42:02
phu_grassman: 金币+20, 翻译EPI+1, thanks for your time and energy 2013-03-01 13:42:02
|
摘要 目的 评估口服抗癌药物（S-1）的有效性和毒性，这种药用于晚期非小细胞肺癌(NSCLC)患者的前期治疗。 患者和方法 患者是先前接收过一次铂化疗的晚期非小细胞肺癌患者。病人连续28天口服s – 1，剂量通过使用基于病人的BSA做的列线图所确定，每6周重复一次。 结果 2005年8月至2007年7月,50个患者参与本研究。6个病人有部分反应(PR), 且符合条件的患者整体反应率为12.5%(6/48) (95%置信区间,3.1 -21.9%)。疾病控制率为39.6% (19/48) (95% 置信区间,25.7 -53.4%)。平均无进展存活时间是2.5个月。平均存活时间是8.2个月,1年的生存率为29.6%。没有遇到4级毒性反应。中性粒细胞减少造成的三级血液毒性患者(2.1%)和贫血各1例(2.1%)。5个病人出现三级非血液毒性 (10.4%)。没有发生与治疗相关的死亡。 结论 s - 1是一种有效的和药物单一治疗具有良好耐受性的晚期非小细胞肺癌二线治疗药物。 本人水平有限，希望能帮到你。  |
2楼2013-03-01 12:45:41
